medigraphic.com

2017, Number 1

<< Back Next >>

Rev Med MD 2017; 8.9 (1)

Conjuntival and Corneal Intraepithelial Neoplasia

Muñoz-Solórzano B, Saucedo-Rodríguez LR, Robles-Yeme D, Mendez-Magaña AC, Lemus-Cruz CV

Language: Spanish
References: 50
Page: 68-76
PDF size: 802.89 Kb.


ABSTRACT

The Conjunctival and Corneal Intraepithelial Neoplasia (CCIN) represents the most frequent non-pigmented malignant tumor of the ocular surface (33.4%), whose risk factor include U-V light, petroleum products or tobacco smoke exposure, use of contact lenses, viral infections, immunodeficiency, etc. Usually, CCIN is presented in advanced age (sixties and seventies decade of life), and is not very common in children. CCIN is a slowly progressive lesion, with low malignant potential, with less than 1% of metastases incidence. The most used therapeutic approach is the surgical excision of the lesion with the use of topical chemotherapy or cryotherapy, however in the last decade, several primary treatment protocols have been developed with topical chemotherapy, using Mitomycin C (MMC), 5 -Fluorouracil (5-FU) and Interferon alfa-2b (INF-2b), getting excellent results, that give the option to a new approach and a decrease in invasive procedures and recurrence rates of the condition.
The objective of this review is to provide more information for doctors and ophthalmologist about this disease and emphasize in new diagnostic options and different treatments to incorporate them into the regular practice.


REFERENCES

  1. Shields C, Chien J, Surakiatchanukul T, et al. Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes. Asia Pac J Ophthalmol. 2017;6:109-120

  2. Basti S, Macsai M. Ocular surface squamous neoplasia: a review. Cornea. 2003;22(7):687-704.

  3. Yanoff, M, Duker, J. Ophthalmology. 4th ed. Pittsburgh: Elsevier/Saunders; 2014: 196-202.

  4. Mittal R, Rath S. Ocular Surface squamous neoplasia- Review of etio-pathogenesis and an update on clinico-pathological diagnosis. Saudi J Ophthalmol. 2013;27:177-186.

  5. Giaconi J, Karp C. Current Treatment Options for Conjunctival and Corneal Intraepithelial Neoplasia. Ocul Surf. 2003; 1: 66-73.

  6. Sayed-Ahmed I, Palioura S, et al. Diagnosis and Medical Management of Ocular Surface Squamous Neoplasia. Expert Rev Ophthalmol. 2017;12(1):11-19.

  7. Gichuhi S, Ohnuma S, Sagoo M. Pathophysiology of ocular surface squamous neoplasia. Exp Eye Res. 2014; 129: 172-182.

  8. Karp C, Scott I, Chang T. Conjunctival Intraepithelial Neoplasia, a possible marker for human inmunodeficiency virus infection?. Ophthalmology. 1996; 114: 257-261.

  9. Ndlovu N, Ndarukwa S, et al. Evaluation of the radiotherapy management of ocular Surface squamous neoplasia in a high HIV prevalence setting- a retrospective review. Infect Agent Cancer. 2016; 11-18.

  10. Scott I, Karp C, et al. Human Papillomavirus 16 and 18 Expression in Conjunctival Intraepithelial Neoplasia. Ophthalmology. 2002; 109: 542-547.

  11. Schechter B, Koreishi A. Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b. Ophthalmology. 2008; 115:1291-1296.

  12. Sharma M, Sundar D, Vanathi M, et al. Invasive Ocular Surface Squamous Neoplasia Masquerading as Nodular Scleritis. Ophthal Plast Reconstr Surg. 2017;33(2):45-47

  13. Murillo J, Wu M, et al. Intracorneal and Intraocular Invasion of Ocular Surface Squamous Neoplasia after Intraocular surgery: Report of Two Cases and Review of the Literature. Ocul Oncol Pathol. 2017; 3:66-72.

  14. Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol. 2010; 94: 555-558.

  15. Tananuvat N, Lertprasertsuk N, et al. Role of Impression Citology in Diagnosis of Ocular Surface Neoplasia. Cornea. 2008; 27: 269-274.

  16. Othman I. Ocular surface tumors. Oman J Ophthalmol. 2009; 2:3-14.

  17. Atallah M, Joag M, Galor A, et al. Role of high resolution optical coherence tomography in diagnosing ocular Surface squamous neoplasia with coexisting ocular Surface diseases. Ocul Surf. 2017. doi: 10.1016/j.jtos.2017.03.003

  18. Maschi C, et al. Benign conjunctival tumors. J Fr Ophtalmol. 2013;36(9):796-802.

  19. Cinotti E. Handheld reflectance confocal microscopy for the diagnosis of conjunctival tumors. Am J Ophthalmol. 2015;159(2):324-33.e1.

  20. Sjo NC, Heegaard S, Prause JU, von Buchwald C, Lindeberg H. Human papillomavirus in conjunctival papilloma. Br J Ophthalmol. 2001; 85: 785-787.

  21. Shields C, Shields J. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49(1):3-24.

  22. Grossniklaus HE. Basic and Clinical Science Course. Section 4. Ophthalmic pathology and intraocular tumors. San Francisco: American Academy of Ophthalmology. 2005; 332.

  23. Mauriello JA Jr, Napolitano J, McLean I. Actinic keratosis and dysplasia of the conjunctiva: a clinicopathological study of 45 cases. Can J Ophthalmol. 1995; 30: 312-316

  24. Pérez Llanes A. Carcinoma de células escamosas de la conjuntiva en adultos jóvenes inmunocompetentes. Rev Cubana Oftalmol. 2014; 27(1):146-151.

  25. Tunc M, Char D, Crawford B, Miller T. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol 1999; 83: 98-103.

  26. Prado Serrano A., Carcinoma de células escamosas de conjuntiva con invasión intraocular. Caso clínico; Rev Mex Oftalmol. 2009;83(4):245-250.

  27. Gómez CG, Isaias I, Vigoa L. Tumores de los anexos oculares. Re v Cubana Oftalmol. 2001;14(2):129-34.

  28. Holbach LM, et al. Differential diagnosis and treatment options for conjunctival tumors. Ophthalmologe. 2007;104(6):521-38.

  29. Gómez Cabrera C. Lesiones pigmentadas de párpado y conjuntiva. Rev Cubana Oftalmol. 2002;15(1):57-61.

  30. Faber M, Schutzer P, Mihm MC. Pigmented lesions of the conjunctiva. J Am Acad Dermat o l. 2000;42(1):145.

  31. Folberg R, Jakobiec FA, Bernardino VB, Iwamoto T. Benign conjunctival melanocytic lesions. Clinicopathologic features. Ophthalmology 1989; 96: 436-461.

  32. Oellers P, Karp CL. Management of Pigmented Conjunctival Lesiones. Ocul Surf. 2012;10(4):251- 263.

  33. Singh A, De Potter P, Fijal B, Shields J, Elston R. Lifetime prevalence of uveal melanoma in white patients with oculo (dermal) melanocytosis. Ophthalmology. 1998;105: 195-198.

  34. De Potter P, Shields C, Shields J, et al. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77(10), 624–630.

  35. Alarcón C, Carrera C, et al. Clinical Usefulness of Reflec tance Confocal Mi c ros copy in the Management of Facial Lentigo Maligna Melanoma. Actas Dermosifiliogr. 2014;105(3):13-17

  36. Wong J, Nanji A, Galor A, et al. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204.

  37. Kenawy N, Lake SL, Coupland SE, Damato BE. Conjunctival melanoma and melanocytic intraepithelial neoplasia. Eye. 2012;27(2):142–152.

  38. Murcia A, Borrás J. Tratamiento farmacológico de la neoplasia corneal y conjuntival. Farm Hosp. 2005;29(1):126-133

  39. Boeta L; Lacy R. Cirugía micrográfica de Mohs. Dermatol Rev Mex. 2013;57:34-40.

  40. Miranda L; Martins M; Pinheiro L. Excision, cryotherapy and mitomycin c for the treatment of conjunctival-corneal intraepithelial neoplasia. Rev Bras Oftalmol. 2016; 75 (5): 391-395.

  41. Agraval U, Rundle P, Rennie I, Salvi S. Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions. Eye. 2017;31(6):884-889.

  42. Divine RD. Nitrous oxide cryotherapy for intraepithelial epithelioma of the conjunctiva. Arch Ophthalmol. 1983; 101:782-788.

  43. Peksayar G, Soytürk M, et al. Long-term Results of Cryotherapy on Malignant Epithelial Tumors of the Conjunctiva. Am J Ophthalmol. 1989; 107:337-349.

  44. Kim J, Abramson D. Topical treatment options for conjunctival neoplasms. Clin Ophthalmol. 2008; 2(3): 503-515.

  45. Daniell M, Maini R. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol. 2002;30(2):94-8.

  46. Russel H, Lockington D, et al. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010; 94:1316- 1321.

  47. Dudney B, Malecha M. Limbal Stem Cell Deficiency Following Topical Mitomycin C Treatment of Conjunctival-Corneal Intraepithelial Neoplasia. Am J Ophthalmol. 2004; 137: 950-951

  48. Ballalai P, Erwenne, C. Long-Term Results of Topical Mitomycin C 0.02% for Primary and Recurrent Conjunctival-Corneal Intraepithelial Neoplasia. Ophthal Plas Reconstr Surg. 2009;25(4):296-9.

  49. Prabhasawat P, Tarinvorakup P, et al. Topical 0.002% Mitomycin C for the Treatment of Conjunctival-Conreal Intraephitelial Neoplasia and Squamous Cell Carcinoma. Cornea. 2005; 24(4):443- 8

  50. Tabin G; Levin S, et al. Late recurrences and the Necessity for Long-term Follow-up in Corneal and Conjunctival Intrapithelial Neoplasia. Ophthalmology 1997;104: 485-492.




2020     |     www.medigraphic.com